· Published by Health Canada · Official notice
This is duplicated text of a letter from Baxter Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 3, 2013
Dear Health Care Professional:
Please distribute to the Peritoneal Dialysis (PD) Program, Nephrology In-Patient Unit and other involved professional staff and post this NOTICE in your institution.
Subject: Unintended Increased Intraperitoneal Volume (IIPV) with HomeChoice and HomeChoice PRO Automated Peritoneal Dialysis (APD) Systems
Baxter, in conjunction with Health Canada is providing this notice to reinforce the importance of proper programming to reduce the potential for unintended Increased Intraperitoneal Volume (IIPV) or overfill of the abdomen in patients using the HomeChoice and HomeChoice PRO APD Systems. Unintended IIPV can occur if the prescription parameters are not programmed appropriately in the dialysis systems and this can lead to serious injury or death.
Baxter is in process of upgrading all HomeChoice cyclers to software version 10.4 to reduce the potential for IIPV situations or events. A review of Post Market Surveillance data on HomeChoice cyclers with software version 10.4 has revealed that IIPV events might still occur predominantly in Tidal APD, associated with incorrect programming of therapy parameters.
Additional Information
Correct programming, particularly of the total ultrafiltration (UF) and the minimum drain volume percentage (MDV%) in Tidal automated peritoneal dialysis (Tidal APD) should be reinforced. Two relevant causes of IIPV in Tidal APD include programming the MDV% too low and inappropriate programming of total UF. The following mitigations address these relevant causes of IIPV, however please refer to the Patient At-Home Guide for additional guidance on IIPV.
Use errors that increase the risk of unintended IIPV are defined within the HomeChoice APD Systems Patient At-Home Guide and should be emphasized with the patient.
Managing marketed health product-related adverse incidents depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse incidents are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious unintended IIPV or other serious or unexpected adverse incidents for medical devices in patients using HomeChoice and HomeChoice PRO APD Systems should be reported to Baxter Corporation or Health Canada at the following addresses:
Baxter Corporation
7125 Mississauga Rd, Mississauga, Ontario L5N 0C2
1-800-553-6898, Prompt 1
To correct your mailing address or fax number, contact Baxter Corporation.
Any suspected adverse incident can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Telephone: The Inspectorate Hotline 1-800-267-9675
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada Web site.
For other medical device inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Phil Lynch
Director, Quality,
Baxter Corporation
Baxter, HOMECHOICE AND HOMECHOICE PRO are registered trademarks of Baxter International, Inc.